CA2484604A1 - .delta. 4,5 glycuronidase and uses thereof - Google Patents

.delta. 4,5 glycuronidase and uses thereof Download PDF

Info

Publication number
CA2484604A1
CA2484604A1 CA002484604A CA2484604A CA2484604A1 CA 2484604 A1 CA2484604 A1 CA 2484604A1 CA 002484604 A CA002484604 A CA 002484604A CA 2484604 A CA2484604 A CA 2484604A CA 2484604 A1 CA2484604 A1 CA 2484604A1
Authority
CA
Canada
Prior art keywords
glycuronidase
glycosaminoglycan
composition
delta
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002484604A
Other languages
French (fr)
Other versions
CA2484604C (en
Inventor
James R. Myette
Zachary Shriver
Ganesh Venkataraman
Ram Sasisekharan
Maitland W. Mclean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2484604A1 publication Critical patent/CA2484604A1/en
Application granted granted Critical
Publication of CA2484604C publication Critical patent/CA2484604C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01056—Glucuronosyl-disulfoglucosamine glucuronidase (3.2.1.56), i.e. glycuronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01166—Heparanase (3.2.1.166)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to .DELTA.4,5 glycuronidase, related compositions, and methods of use thereof.

Claims (49)

1. A substantially pure .DELTA.4,5 unsaturated glycuronidase.
2. The glycuronidase of claim 1, wherein the glycuronidase is a recombinantly produced glycuronidase.
3. The glycuronidase of claim 1, wherein the glycuronidase is a synthetic glycuronidase.
4. The glycuronidase of claim 1, wherein the glycuronidase is a peptide having an amino acid sequence of SEQ ID NO:1, or a functional variant thereof.
5. An isolated polypeptide comprising:
.DELTA.4,5 unsaturated glycuronidase having an amino acid sequence of SEQ ID
NO: 1 or a functional variant thereof.
6. The isolated polypeptide of claim 5, wherein the glycuronidase has the amino acid sequence of SEQ ID NO: 1.
7. A composition comprising, an isolated .DELTA.4,5 unsaturated glycuronidase having a higher specific activity than native glycuronidase.
8. The composition of claim 7, wherein the glycuronidase has a specific activity of at least about 60 picomoles of substrate hydrolyzed per minute per picomole of glycuronidase.
9. The composition of claim 7, wherein the .DELTA.4,5 unsaturated glycuronidase has at least about a two fold higher specific activity than native glycuronidase.
10. The composition of claim 7, wherein the .DELTA.4,5 unsaturated glycuronidase has at least about a three fold higher specific activity than native glycuronidase.
11. The composition of claim 7, wherein the .DELTA.4,5 unsaturated glycuronidase has at least about a four fold higher specific activity than native glycuronidase.
12. An isolated nucleic acid molecule selected from the group consisting of (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:2, and which code for .DELTA.4,5 unsaturated glycuronidase having an amino acid sequence set forth as SEQ ID
NO:1, (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to degeneracy of the genetic code, and (c) complements of (a) or (b).
13. The isolated nucleic acid molecule of claim 12, wherein the isolated nucleic acid molecule codes for SEQ ID NO:1.
14. The isolated nucleic acid molecule of claim 12, wherein the isolated nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:2.
15. An expression vector comprising the isolated nucleic acid molecule of claim 10 operably linked to a promoter.
16. A host cell comprising the expression vector of claim 15.
17. An expression vector comprising the isolated nucleic acid molecule of claim 14 operably linked to a promoter.
18. A host cell comprising the expression vector of claim 17.
19. A pharmaceutical preparation comprising:
a composition or vector of any of claims 1-15 and a pharmaceutically acceptable carrier.
20. A method of cleaving a glycosaminoglycan, comprising:
contacting a glycosaminoglycan with the glycuronidase of any one of claims 1-in an effective amount to cleave the glycosaminoglycan.
21. A glycosaminoglycan prepared according to the method of claim 20.
22. A method of removing heparin from a heparin containing fluid, comprising:
contacting a heparin containing fluid with the glycuronidase of any one of claims 1-10 in an effective amount to removing heparin from the heparin containing fluid.
23. The method of claim 22, wherein the glycuronidase is immobilized on a solid support.
24. The method of claim 23, wherein heparinase is also immobilized on the solid support.
25. A method of analyzing of a glycosaminoglycan, comprising:
contacting a glycosaminoglycan with the glycuronidase of any one of claims 1-in an effective amount to analyze the glycosaminoglycan.
26. The method of claim 25, wherein the method is a method for identifying the presence of a particular glycosaminoglycan in a sample.
27. The method of claim 25, wherein the method is a method for determining the purity of a glycosaminoglycan in a sample.
28. The method of claim 25, wherein the method is a method for determining the composition of a glycosaminoglycan in a sample.
29. The method of claim 25, wherein the method is a method for determining the sequence of saccharide units in a glycosaminoglycan.
30. The method of claim 29, further comprising an additional analytic technique selected from the group consisting of mass spectrometry, NMR spectroscopy, gel electrophoresis, capillary electrophoresis, and HPLC.
31. A method of cleaving a glycosaminoglycan comprised of at least one disaccharide unit, comprising:
contacting a glycosaminoglycan comprised of at least one disaccharide unit with the glycuronidase of any one of claims 1-10 in an effective amount to cleave the glycosaminoglycan.
32. The method of claim 31, wherein the glycosaminoglycan is comprised of .DELTA.UH NAc disaccharide units.
33. The method of claim 31, wherein the glycosaminoglycan is comprised .DELTA.UH NAc,6S disaccharide units.
34. The method of claim 31, wherein the glycosaminoglycan is comprised of .DELTA.UH NS,6S disaccharide units.
35. The method of claim 31, wherein the glycosaminoglycan is comprised of .DELTA.UH NS disaccharide units.
36. The method of claim 31, wherein the glycosaminoglycan length exceeds two saccharide units.
37. The method of claim 30, wherein the glycosaminoglycan does not contain a 2-0 sulfated uronidate.
38. The method of claim 30, wherein the glycosaminoglycan is 6-0 sulfated.
39. The method of claim 30, wherein the glycosaminoglycan does contain an N-unsubstituted glycosamine.
40. A method of inhibiting angiogenesis, comprising administering to a subject in need thereof an effective amount of the pharmaceutical preparation of claim 19 for inhibiting angiogenesis.
41. A method of treating cancer, comprising administering to a subject in need thereof an effective amount of the pharmaceutical preparation of claim 19 for treating cancer.
42. A method of inhibiting cellular proliferation, comprising administering to a subject in need thereof an effective amount of the pharmaceutical preparation of claim 19 for of inhibiting cellular proliferation.
43. A method of treating a coagulation disorder, comprising administering the composition of claim 19 to a subject in need thereof an effective amount for treat the coagulation disorder.
44. The method of any one of claims 20, 22, or 31, wherein the use of the glycuronidase is concurrent with or follows treatment with heparinase.
45. A pharmaceutical preparation comprising:
a composition of claim 19 and a pharmaceutically acceptable carrier.
46. A method of inhibiting angiogenesis, comprising administering the composition of claim 21 to a subject in need thereof an effective amount for inhibiting angiogenesis.
47. A method of treating cancer, comprising administering the composition of claim 21 to a subject in need thereof an effective amount for treating cancer.
48. A method of inhibiting cellular proliferation, comprising administering the composition of claim 21 to a subject in need thereof an effective amount for inhibiting cellular proliferation.
49. A method of treating a coagulation disorder, comprising administering the composition of claim 21 to a subject in need thereof an effective amount for treat the coagulation disorder.
CA2484604A 2002-05-03 2003-05-05 .delta. 4,5 glycuronidase and uses thereof Expired - Fee Related CA2484604C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37748802P 2002-05-03 2002-05-03
US60/377,488 2002-05-03
PCT/US2003/013938 WO2004069152A2 (en) 2002-05-03 2003-05-05 Δ4,5 glycuronidase and uses thereof

Publications (2)

Publication Number Publication Date
CA2484604A1 true CA2484604A1 (en) 2004-08-19
CA2484604C CA2484604C (en) 2011-08-02

Family

ID=32850488

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2484604A Expired - Fee Related CA2484604C (en) 2002-05-03 2003-05-05 .delta. 4,5 glycuronidase and uses thereof

Country Status (7)

Country Link
US (7) US20050214276A9 (en)
EP (1) EP1575534B1 (en)
JP (2) JP4416664B2 (en)
AU (2) AU2003303301B2 (en)
CA (1) CA2484604C (en)
ES (1) ES2421134T3 (en)
WO (1) WO2004069152A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1109919A2 (en) * 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
CA2370539C (en) * 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
CA2402160C (en) * 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
AU2001292618A1 (en) * 2000-09-12 2002-03-26 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
AU2440802A (en) 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
EP1575534B1 (en) * 2002-05-03 2013-04-10 Massachusetts Institute Of Technology D4,5 glycuronidase and uses thereof
WO2004055491A2 (en) * 2002-05-20 2004-07-01 Massachusetts Institute Of Technology Novel method for sequence determination using nmr
CA2493509C (en) * 2002-06-03 2010-03-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
JP4606712B2 (en) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
EP1737954A2 (en) * 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
US20110008327A1 (en) * 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
MXPA06011219A (en) 2004-03-29 2007-05-08 Univ South Florida Effective treatment of tumors and cancer with triciribine and related compounds.
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100009928A1 (en) * 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005111627A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
WO2006083328A2 (en) * 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
CN1870631B (en) * 2005-11-11 2010-04-14 华为技术有限公司 Gate control method of media gateway
WO2007120478A2 (en) * 2006-04-03 2007-10-25 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
CA2674493C (en) * 2007-01-05 2017-05-09 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
EP4015523A1 (en) * 2010-05-05 2022-06-22 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
KR101398764B1 (en) 2013-08-29 2014-05-27 강릉원주대학교산학협력단 Device for detecting analytes by moving the particle and method using the same
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN108431024A (en) * 2015-10-16 2018-08-21 堪萨斯州立大学研究基金会 3 type circovirus immunogenic composition of pig and its preparation and application
CN106018597B (en) * 2016-05-18 2018-12-21 山东大学 A kind of hydrophilic interaction chromatography multiple-reaction monitoring second order ms combination detection method of the basic component units of low molecular weight heparin
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217863B1 (en) * 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
EP1109919A2 (en) * 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US7056504B1 (en) * 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
IL127851A0 (en) 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
CA2370539C (en) * 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
EP1192187A1 (en) 1999-06-30 2002-04-03 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors
CA2402160C (en) * 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
DE10026699A1 (en) * 2000-05-30 2001-12-06 Basf Ag Formulation based on heparin, glycosaminoglycan or heparinoid and use of the formulation and the formulation base
AU2001292618A1 (en) * 2000-09-12 2002-03-26 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
AU2440802A (en) * 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
JP2005503120A (en) 2001-03-27 2005-02-03 マサチューセッツ　インスティテュート　オブ　テクノロジー Methods and products for FGF dimerization
EP1575534B1 (en) * 2002-05-03 2013-04-10 Massachusetts Institute Of Technology D4,5 glycuronidase and uses thereof
WO2004055491A2 (en) * 2002-05-20 2004-07-01 Massachusetts Institute Of Technology Novel method for sequence determination using nmr
CA2493509C (en) * 2002-06-03 2010-03-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
JP4606712B2 (en) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
US7851223B2 (en) * 2004-02-27 2010-12-14 Roar Holding Llc Method to detect emphysema
EP1737954A2 (en) * 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005110438A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
WO2006083328A2 (en) 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
AP2007004081A0 (en) * 2004-12-23 2007-08-31 Basf Ag Fungicidal mixtures
CA2594013A1 (en) * 2005-01-12 2006-07-20 Massachusetts Institute Of Technology Methods and compositions related to modulating the extracellular stem cell environment
US20090155875A1 (en) 2005-02-16 2009-06-18 Massachusetts Institute Of Technology Methods to Enhance Carbon Monoxide Dehydrogenase Activity and Uses Thereof
US20090156477A1 (en) 2005-03-29 2009-06-18 Massachusetts Institute Of Technology Compositions and Methods for Regulating Inflammatory Responses
WO2006105313A2 (en) 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions of and methods of using oversulfated glycosaminoglycans
US20060258610A1 (en) * 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
JP2007184847A (en) * 2006-01-10 2007-07-19 Nec Electronics Corp Clock and data recovery circuit and serdes circuit
WO2007120478A2 (en) 2006-04-03 2007-10-25 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
CA2674493C (en) 2007-01-05 2017-05-09 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum

Also Published As

Publication number Publication date
US20060177885A1 (en) 2006-08-10
ES2421134T3 (en) 2013-08-29
JP2009297029A (en) 2009-12-24
EP1575534A2 (en) 2005-09-21
AU2008243128B2 (en) 2011-11-24
EP1575534A4 (en) 2008-05-21
US20100129868A1 (en) 2010-05-27
JP2006504437A (en) 2006-02-09
AU2003303301A1 (en) 2004-08-30
JP4416664B2 (en) 2010-02-17
US20040091471A1 (en) 2004-05-13
US7695711B2 (en) 2010-04-13
AU2008243128A1 (en) 2008-11-27
US20060177910A1 (en) 2006-08-10
EP1575534B1 (en) 2013-04-10
US20050214276A9 (en) 2005-09-29
US20060183891A1 (en) 2006-08-17
US20120045425A1 (en) 2012-02-23
WO2004069152A3 (en) 2006-04-27
AU2003303301B2 (en) 2008-08-07
WO2004069152A2 (en) 2004-08-19
US20060177911A1 (en) 2006-08-10
CA2484604C (en) 2011-08-02
US7951560B2 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
CA2484604A1 (en) .delta. 4,5 glycuronidase and uses thereof
JP2006504437A5 (en)
Odink et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis
Choi et al. Characterization of the dermatan sulfate proteoglycans, DS-PGI and DS-PGII, from bovine articular cartilage and skin isolated by octyl-sepharose chromatography
JP2004208684A5 (en)
Hascall Interaction of cartilage proteoglycans with hyaluronic acid
Clark-Lewis et al. Chemical synthesis, purification, and characterization of two inflammatory proteins, neutrophil activating peptide 1 (interleukin-8) and neutrophil activating peptide 2
Kelly et al. Second proteasome-related gene in the human MHC class II region
ERNST et al. Expression in Escherichia coli, purification and characterization of heparinase I from Flavobacterium heparinum
Olafson et al. Amino acid sequence of Streptomyces griseus trypsin. Cyanogen bromide fragments and complete sequence
Chauvet et al. The reactive site of the basic trypsin inhibitor of pancreas: role of lysine 15
Gibney et al. Divergence in primary structure between the molecular forms of acetylcholinesterase.
AU638402B2 (en) Analogs of fibroblast growth factor
Dissing et al. Human red cell acid phosphatase (ACP1). The amino acid sequence of the two isozymes Bf and Bs encoded by the ACP1* B allele.
Acharya et al. Crosslinking of elongation factor EF-G to the 50S ribosomal subunit of Escherichia coli
Gutte A synthetic 70-amino acid residue analog of ribonuclease S-protein with enzymic activity.
Vladimirov et al. Characterization of the human small‐ribosomal‐subunit proteins by N‐terminal and internal sequencing, and mass spectrometry
CA2493509A1 (en) Rationally designed polysaccharide lyases derived from chondroitinase b
Litman et al. Evidence for a conformational change in the 30 S E. coli ribosomal subunit upon formation of 70 S particles
US5814314A (en) Non-glycosylated, recombinant human IL 2 in reduced form
Carlson Chemistry and biosynthesis of mucin glycoproteins
Kawarasaki et al. Phosphatase-immunodepleted cell-free protein synthesis system
Bhargava et al. Studies on glycoproteins: XIV. O-seryl-N-acetylgalactosaminide glycosidase, the enzyme splitting the O-glycosidic linkage between carbohydrate and peptide in ovine submaxillary glycoprotein
Roberts et al. A structural comparison of the subunits of the Dolichos biflorus seed lectin by peptide mapping and carboxyl terminal amino acid analysis
Yuki et al. Charge isomers of urinary bikunin (trypsin inhibitor)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210505